When was Keylika founded?

Keylika was founded in 2022 and raised its 1st funding round within a year of its incorporation.

Where is Keylika located?

Keylika is headquartered in Walnut Creek, United States.

How many employees does Keylika have?

As of Jun 30, 2026, the latest employee count at Keylika is 3.

Is Keylika a funded company?

Keylika is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on 2022.

When was the latest funding round of Keylika?

Keylika's latest funding was a $***** Seed round on 2022, with participation from 1 investor. Its primary sector is Drug Delivery. In United States, the Drug Delivery sector has seen $232M in funding in 2026 to date.

Where does Keylika rank among its competitors?

Keylika ranks 43rd amongst 76 active competitors, of which 29 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was CeQur, which secured $100M in Jun, 2026.

Who are the top competitors of Keylika?

Keylika's top competitors include scPharmaceuticals, Vaxxas and CeQur. Among them, CeQur secured the most recent funding round in June, 2026.

Keylika - 2026 Company Profile, Team, Funding & Competitors

Keylika is a seed company based in Walnut Creek (United States), founded in 2022 by Frederik Ceyssens. It operates as a Developer of transdermal patch for drug delivery. Keylika has raised $500K in funding from Y Combinator. The company has 76 active competitors, including 29 funded and 13 that have exited. Its top competitors include companies like scPharmaceuticals, Vaxxas and CeQur.

Company Details

Developer of transdermal patch for drug delivery. The company's product is a novel iron complex administered by a wearable transdermal patch for treating Iron deficiency anemia (IDA) and gastrointestinal diseases.

Website: www.keylika.com/
Social
Email ID: *****@keylika.com
Phone Number: +1 **********

Key Metrics

Founded Year

2022

Location

Walnut Creek, United States

Stage

Seed

Total Funding

$500K in 1 round

Latest Funding Round

Seed, 2022, $*****

Investors

Y Combinator & 1 more

Ranked

43^rd among 76 active competitors

Employee Count

3 as on Jun 30, 2026

Similar Companies

scPharmaceuticals & 97 more

View Keylika's full profile

Keylika has raised a total funding of $500K over 1 round. Its latest funding round was a Seed round on 2022 for $*****. 1 investor participated in its latest round. Keylika has 2 institutional investors.

Here is the list of recent funding rounds of Keylika:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
2022	1011	Seed	4376	9772	3714	7238

Access funding benchmarks and valuations. Sign up today!

View details of Keylika's funding rounds and investors

The founders of Keylika is Frederik Ceyssens.

Here are the details of Keylika's key team members:

Frederik Ceyssens: Co-Founder of Keylika.
Contact Info: 1 email address

View details of Keylika's Founder profiles and Board Members

Keylika's employee count trend

Keylika has 3 employees as of Jun 26. Here is Keylika's employee count trend over the years:

Uncover Keylika's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Keylika include scPharmaceuticals, Vaxxas and CeQur. Here is the list of Top 10 competitors of Keylika, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	scPharmaceuticals 2013, Lexington (United States), Acquired	Provider of a device for subcutaneous drug delivery for the treatment of bacterial infections and heart failure	$78.7M	Orbimed, Sun Pharma & 4 others	60/100
2nd	Vaxxas 2010, Brisbane (Australia), Series D	Developer of a needle-free patch technology for vaccine delivery applications	$91.2M	One Ventures, UniQuest & 12 others	59/100
3rd	CeQur 2008, Horw (Switzerland), Series E	Developer of wearable insulin delivery patch	$492M	Endeavour Vision, Schroders & 7 others	59/100
4th	BioSapien 2018, New York City (United States), Seed	Developer of 3D-printed drug delivery platforms for targeted pharmaceutical agents	$10.6M	JPIN, SOSV & 13 others	57/100
5th	Hero Patch 2019, Boston (United States), Series A	Developer of antibodies or small molecules for drug delivery	$20.5M	Velocity Partners, Big Pi Ventures & 5 others	55/100
6th	Starton 2017, New York City (United States), Seed	Developer of drug delivery solution and drugs for treating oncology	$9.29M	LOVE Pharma, Goldfingr	52/100
7th	Scilex Holding 2019, Palo Alto (United States), Public	Developer of non-opioid therapies for acute and chronic pain	-	Frazier Life Sciences	52/100
8th	Corsair Phama 2014, San Francisco (United States), Series B	Developer of drugs for the treatemnt of cardiac diseases	$23M	New Rhein, Primavera & 3 others	51/100
9th	AFYX Therapeutics 2013, Copenhagen (Denmark), Series A	Developer of drug patches for the treatment of mucosal diseases	$33.3M	Sofinnova Investments, Nordic Venture & 6 others	48/100
10th	Valeritas 2003, Bridgewater (United States), Acquired	Developer of wearable insulin patch pumps for insulin delivery through the skin	$231M	Welsh, Carson, Anderson & Stowe, Abingworth ... & 12 others	46/100
43rd	Keylika 2022, Walnut Creek (United States), Seed	Developer of transdermal patch for drug delivery	$500K	Y Combinator, Fundament	28/100